Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran.
Department of Pharmacology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Inflammopharmacology. 2023 Oct;31(5):2641-2652. doi: 10.1007/s10787-023-01293-y. Epub 2023 Aug 3.
Neuropathic pain results from lesions or diseases affecting the somatosensory system. The management of a patient with chronic neuropathic pain remains a challenge several studies report the analgesic effect of serotonin receptor antagonists in different models of experimental pain. The present study was designed to study the effect of systemic administration of risperidone, on behavioral scores of neuropathic pains in chronic constriction (CCI) model in rats.
Inducing neuropathic pain with the CCI model which causes heat hyperalgesia, heat, and mechanical allodynia was performed on rats, and then, in two phases, risperidone effect was determined. In the acute phase, risperidone 1, 2, 4 mg was administered for three groups half an hour before behavioral tests on the 7th, 14th, and 21st day after surgery, and in the chronic phase, risperidone 1, 2, and 4 mg was administered for three different groups from the 1st to 14th days after surgery than on 14th-day behavioral scores were performed. For gene expression analysis, samples are taken from spinal cord tissues in lumbar segments.
This study shows chronic administration of risperidone as an antipsychotic drug was effective on heat hyperalgesia and allodynia. However, only the max dosage (4 mg) of risperidone showed meaningful improvement in increasing mechanical allodynia. However, acute administering of risperidone did not show any meaningful changes in behavioral tests on neuropathic pain induced by chronic constriction injury of the sciatic nerve in rats. In addition, gene expression results showed an increase in IL-4 and IL-10 gene expression in the risperidone group compared to the sham group.
This study suggests the helpful preventive effects of risperidone in developing and increasing neuropathic pain, but it does not have any instant effect.
神经病理性疼痛是由影响躯体感觉系统的损伤或疾病引起的。慢性神经病理性疼痛患者的管理仍然是一个挑战，几项研究报告了 5-羟色胺受体拮抗剂在不同实验性疼痛模型中的镇痛作用。本研究旨在研究利培酮系统给药对慢性缩窄性损伤（CCI）模型大鼠神经病理性疼痛行为评分的影响。
用 CCI 模型诱导神经病理性疼痛，该模型导致热痛觉过敏、热和机械性痛觉过敏，然后在两个阶段确定利培酮的作用。在急性期，利培酮 1、2、4mg 分别在术后第 7、14 和 21 天进行行为测试前半小时给予三组，在慢性期，利培酮 1、2 和 4mg 分别在术后第 1 至 14 天给予三组，而在第 14 天进行行为评分。为了进行基因表达分析，从腰椎段脊髓组织中取样。
本研究表明，作为一种抗精神病药物的利培酮慢性给药对热痛觉过敏和痛觉过敏有效。然而，只有最大剂量（4mg）的利培酮显示出对机械性痛觉过敏的有意义的改善。然而，急性给予利培酮在大鼠坐骨神经慢性缩窄性损伤引起的神经病理性疼痛的行为测试中没有显示出任何有意义的变化。此外，基因表达结果显示，与假手术组相比，利培酮组的 IL-4 和 IL-10 基因表达增加。
本研究表明利培酮具有预防神经病理性疼痛发展和加重的有益作用，但没有即时作用。
